Biofil Chemicals Financials
| BIOFILCHEM | 62.77 0.86 1.39% |
Operating Margin 0.0283 | PE Ratio 187.6061 | Profit Margin 0.0138 | Return On Equity 0.04 |
Biofil | Select Account or Indicator |
Understanding current and past Biofil Chemicals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biofil Chemicals' financial statements are interrelated, with each one affecting the others. For example, an increase in Biofil Chemicals' assets may result in an increase in income on the income statement.
Please note, the presentation of Biofil Chemicals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biofil Chemicals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biofil Chemicals' management manipulating its earnings.
Biofil Chemicals Stock Summary
Biofil Chemicals competes with Kingfa Science, Rico Auto, GACM Technologies, COSMO FIRST, and Tribhovandas Bhimji. Biofil Chemicals is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE829A01014 |
| Business Address | 1112, Sector E, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biofilgroup.net |
| Phone | 91 73 1272 3016 |
You should never invest in Biofil Chemicals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biofil Stock, because this is throwing your money away. Analyzing the key information contained in Biofil Chemicals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Biofil Chemicals Key Financial Ratios
Biofil Chemicals' financial ratios allow both analysts and investors to convert raw data from Biofil Chemicals' financial statements into concise, actionable information that can be used to evaluate the performance of Biofil Chemicals over time and compare it to other companies across industries.| Revenue | 400.35 M | ||||
| Gross Profit | 25.63 M | ||||
| EBITDA | 13.06 M | ||||
| Net Income | 7.09 M | ||||
| Cash And Equivalents | 260 K |
Biofil Chemicals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 423.6M | 332.4M | 187.3M | 314.1M | 470.8M | 242.1M | |
| Other Current Liab | 15.6M | 1.4M | 1.6M | 933K | 2.9M | 3.9M | |
| Net Debt | 9.4M | (107K) | 3.2M | 5.0M | (18.4M) | (17.5M) | |
| Retained Earnings | (350.1M) | (337.7M) | (330.6M) | (128.5M) | (318.3M) | (334.2M) | |
| Accounts Payable | 259.2M | 158.5M | 6.0M | 126.5M | 275.5M | 289.3M | |
| Cash | 2.6M | 4.4M | 1.5M | 260K | 22.8M | 24.0M | |
| Net Receivables | 299.2M | 186.0M | 71.8M | 205.0M | 330.3M | 346.8M | |
| Inventory | 16.9M | 43.4M | 12.9M | 12.1M | 25.5M | 26.8M | |
| Other Current Assets | 303.2M | 793K | 7.0M | 6.5M | 5.5M | 5.2M | |
| Total Liab | 274.8M | 171.1M | 18.9M | 141.0M | 288.8M | 303.2M | |
| Total Current Assets | 322.7M | 234.6M | 93.1M | 224.1M | 384.1M | 403.3M | |
| Short Term Debt | 11.9M | 4.3M | 4.6M | 2.9M | 4.4M | 4.2M | |
| Net Tangible Assets | 136.5M | 148.8M | 161.3M | 168.4M | 193.6M | 140.0M | |
| Short Long Term Debt | 11.9M | 4.3M | 4.6M | 5.2M | 4.4M | 4.2M | |
| Net Invested Capital | 160.8M | 165.6M | 173.0M | 178.2M | 186.4M | 182.9M | |
| Cash And Equivalents | 2.6M | 4.4M | 1.4M | 260K | 234K | 222.3K | |
| Net Working Capital | 47.9M | 67.1M | 78.2M | 86.8M | 98.8M | 71.0M |
Biofil Chemicals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.2M | 642K | 390K | 425K | 415K | 738.5K | |
| Total Revenue | 296.9M | 357.5M | 223.8M | 300.4M | 400.4M | 420.4M | |
| Gross Profit | 43.8M | 33.2M | 29.2M | 21.4M | 25.3M | 21.7M | |
| Operating Income | 15.6M | 19.6M | 10.3M | 8.3M | 20.7M | 21.7M | |
| Ebit | 16.1M | 19.6M | 10.6M | 8.4M | 9.1M | 9.9M | |
| Ebitda | 20.2M | 23.7M | 14.8M | 12.6M | 13.1M | 12.9M | |
| Cost Of Revenue | 253.1M | 324.3M | 194.6M | 279.0M | 375.1M | 393.8M | |
| Income Before Tax | 14.6M | 19.2M | 10.1M | 7.9M | 8.7M | 8.6M | |
| Net Income | 12.1M | 12.4M | 7.0M | 5.6M | 7.1M | 6.7M | |
| Income Tax Expense | 2.6M | 6.8M | 3.2M | 2.3M | 1.6M | 1.9M | |
| Research Development | 46K | 118K | 224K | 104K | 119.6K | 79.0K | |
| Tax Provision | 2.6M | 6.8M | 3.2M | 2.3M | 1.6M | 2.4M | |
| Net Interest Income | (1.0M) | (681K) | (406K) | (425K) | (415K) | (435.8K) |
Biofil Chemicals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Biofil Chemicals Pha. It measures of how well Biofil is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Biofil Chemicals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Biofil had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Biofil Chemicals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.0M) | (26.5M) | 30.5M | 797K | (13.4M) | (12.7M) | |
| Change In Cash | 1.2M | 1.8M | (3.0M) | (1.1M) | 22.5M | 23.6M | |
| Free Cash Flow | 8.4M | 5.4M | (2.9M) | (1.2M) | 23.7M | 24.9M | |
| Depreciation | 4.3M | 4.2M | 4.3M | 4.3M | 4.0M | 3.2M | |
| Other Non Cash Items | 146K | (6.1M) | (2.7M) | (2.9M) | 2.3M | 2.5M | |
| Capital Expenditures | 2.1M | 5.7M | 699K | 106K | 229K | 217.6K | |
| Net Income | 14.6M | 19.2M | 10.1M | 7.9M | 7.1M | 9.3M | |
| End Period Cash Flow | 2.6M | 4.4M | 1.4M | 376K | 22.8M | 24.0M | |
| Net Borrowings | 788K | (4.5M) | (7.6M) | 348K | 313.2K | 328.9K | |
| Change To Netincome | 1.6M | 1.5M | 725K | 508K | 584.2K | 898.9K | |
| Investments | (2.1M) | (961K) | (699K) | (106K) | (229K) | (240.5K) |
Biofil Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biofil Chemicals's current stock value. Our valuation model uses many indicators to compare Biofil Chemicals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biofil Chemicals competition to find correlations between indicators driving Biofil Chemicals's intrinsic value. More Info.Biofil Chemicals Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biofil Chemicals Pharmaceuticals is roughly 2.78 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biofil Chemicals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biofil Chemicals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Biofil Chemicals Pha Systematic Risk
Biofil Chemicals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biofil Chemicals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Biofil Chemicals Pha correlated with the market. If Beta is less than 0 Biofil Chemicals generally moves in the opposite direction as compared to the market. If Biofil Chemicals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biofil Chemicals Pha is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biofil Chemicals is generally in the same direction as the market. If Beta > 1 Biofil Chemicals moves generally in the same direction as, but more than the movement of the benchmark.
Biofil Chemicals Pharmaceuticals Common Stock Shares Outstanding Over Time
Biofil Chemicals Thematic Clasifications
Biofil Chemicals Pharmaceuticals is part of several thematic ideas from Chemicals Makers to Synthetics. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasBiofil Chemicals November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biofil Chemicals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biofil Chemicals Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biofil Chemicals Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Biofil Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biofil Chemicals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 25.08 | |||
| Value At Risk | (4.53) | |||
| Potential Upside | 5.41 |
Complementary Tools for Biofil Stock analysis
When running Biofil Chemicals' price analysis, check to measure Biofil Chemicals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofil Chemicals is operating at the current time. Most of Biofil Chemicals' value examination focuses on studying past and present price action to predict the probability of Biofil Chemicals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofil Chemicals' price. Additionally, you may evaluate how the addition of Biofil Chemicals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |